Antimicrobial strategies: Inhibition of viral polymerases by 3′-hydroxyl nucleosides

Drugs

Volumn 69, Issue 2, 2009, Pages 151-166

  Deval, Jerome ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYLNUCLEOSIDE DERIVATIVE; 4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 5 HYDROXYDEOXYCYTIDINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; CLEVUDINE; ENTECAVIR; GANCICLOVIR; KP 1212; KP 1461; NORTH METHANOCARBATHYMIDINE; NUCLEOSIDE ANALOG; PENCICLOVIR; PROTEINASE INHIBITOR; PSI 6130; R 7128; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TARIBAVIRIN; TELBIVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VALTORCITABINE; VIRUS POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; BASE MISPAIRING; BINDING AFFINITY; CLINICAL TRIAL; DRUG ACTIVATION; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; HEMOLYTIC ANEMIA; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NEUTROPENIA; NONHUMAN; PHOSPHORYLATION; POLYMERIZATION; REVIEW; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA-DIRECTED DNA POLYMERASE; DNA-DIRECTED RNA POLYMERASES; HUMANS; NUCLEOSIDES; VIRUS DISEASES; VIRUS REPLICATION;

EID: 60549106419     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969020-00002     Document Type: Review

References (54)

1. Gotte M. Effects of nucleotides and nucleotide analogue inhibitors of HIV-1 reverse transcriptase in a ratchet model of polymerase translocation. Curr Pharm Des 2006; 12: 1867-77
2. Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A 1977; 74: 5716-20
3. Datema R, Ericson AC, Field HJ, et al. Critical determinants of antiherpes efficacy of buciclovir and related acyclic guanosine analogs. Antiviral Res 1987; 7: 303-16
4. Lowe DM, Alderton WK, Ellis MR, et al. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob Agents Chemother 1995; 39: 1802-8
5. Reardon JE. Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogues: kinetics of incorporation into DNA and induction of inhibition. J Biol Chem 1989; 264: 19039-44
6. Reid R, Mar EC, Huang ES, et al. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases: a unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl) guanine triphosphate. J Biol Chem 1988; 263: 3898-904
7. Earnshaw DL, Bacon TH, Darlison SJ, et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicellazoster virus. Antimicrob Agents Chemother 1992; 36: 2747-57
8. Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 1997; 41: 594-9
9. Magee WC, Aldern KA, Hostetler KY, et al. Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob Agents Chemother 2008; 52: 586-97
10. Innaimo SF, Seifer M, Bisacchi GS, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41: 1444-8
11. McMahon MA, Jilek BL, Brennan TP, et al. HBV drug entecavir-effects on HIV-1 replication and resistance. N Engl J Med 2007; 356: 2614-21
12. Langley DR, Walsh AW, Baldick CJ, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007; 81: 3992-4001
13. Tchesnokov EP, Obikhod A, Schinazi RF, et al. Delayed chain-termination protects the anti-HBV drug entecavir from excision by HIV-1 reverse transcriptase. J Biol Chem 2008; 283 (49): 34218-28
14. Ding J, Das K, Hsiou Y, et al. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. J Mol Biol 1998; 284: 1095-111
15. Jacobo-Molina A, Ding J, Nanni RG, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A 1993; 90: 6320-4
16. Boyer PL, Julias JG, Marquez VE, et al. Fixed conformation nucleoside analogs effectively inhibit excision-proficient HIV-1 reverse transcriptases. J Mol Biol 2005; 345: 441-50
17. Toniutto P, Fabris C, Bitetto D, et al. Valopicitabine dihydrochloride: a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs 2007; 8: 150-8
18. Migliaccio G, Tomassini JE, Carroll SS, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003; 278: 49164-70
19. Stuyver LJ, McBrayer TR, Whitaker T, et al. Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2′-deoxy-2′- fluorocytidine. Antimicrob Agents Chemother 2004; 48: 651-4
20. Tisdale M, Ellis M, Klumpp K, et al. Inhibition of influenza virus transcription by 2′-deoxy-2′-fluoroguanosine. Antimicrob Agents Chemother 1995; 39: 2454-8
21. Clark JL, Hollecker L, Mason JC, et al. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J Med Chem 2005; 48: 5504-8
22. Murakami E, Bao H, Basavapathruni A, et al. Mechanism of action of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl) thymine as an anti-HIV agent. Antivir Chem Chemother 2007; 18: 83-92
23. Ma H, Jiang WR, Robledo N, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2′-Deoxy- 2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 2007; 282: 29812-20
24. Murakami E, Niu C, Bao H, et al. The mechanism of action of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-D-2′-deoxy-2′-fluoro- 2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008; 52: 458-64
25. Stuyver LJ, McBrayer TR, Tharnish PM, et al. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro-2′-C- methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 2006; 17: 79-87
26. Smith DB, Martin JA, Klumpp K, et al. Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg Med Chem Lett 2007; 17: 2570-6
27. Klumpp K, Leveque V, Le Pogam S, et al. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006; 281: 3793-9
28. Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008; 48 (2): 385-97
29. Kodama EI, Kohgo S, Kitano K, et al. 4′-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 2001; 45: 1539-46
30. Ohrui H. 2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Rec 2006; 6: 133-43
31. Siddiqui MA, Hughes SH, Boyer PL, et al. A 4′-C-ethynyl-2′, 3′-dideoxynucleoside analogue highlights the role of the 3′-OH in anti-HIV active 4′-C-ethynyl-2′-deoxy nucleosides. J Med Chem 2004; 47: 5041-8
32. Boyer PL, Julias JG, Ambrose Z, et al. The nucleoside analogs 4′C-methyl thymidine and 4′C-ethyl thymidine block DNA synthesis by wild-type HIV-1 RT and excision proficient NRTI resistant RT variants. J Mol Biol 2007; 371: 873-82
33. Chen MS, Suttmann RT, Papp E, et al. Selective action of 4′-azidothymidine triphosphate on reverse transcriptase of human immunodeficiency virus type 1 and human DNA polymerases alpha and beta. Biochemistry 1993; 32: 6002-10
34. Witkowski JT, Robins RK, Sidwell RW, et al. Design, synthesis, and broad spectrum antiviral activity of 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 1972; 15: 1150-4
35. Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-9
36. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6: 1375-9
37. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001; 98: 6895-900
38. Crotty S, Cameron C, Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med 2002; 80: 86-95
39. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A 2003; 100: 7289-94
40. Vignuzzi M, Stone JK, Andino R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res 2005; 107: 173-81
41. Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drugs 2002; 3: 680-3
42. Hong Z, Zhong W, Hamatake R, et al. Antiviral activities of new generation of ribavirin analogues: levovirin and viramidine. Hepatology 2001; 34 (4 Pt 2): 415A
43. Kearney KR, Thornton JJ, Navarro VJ. Taribavirin for the treatment of chronic hepatitis C. Expert Opin Pharmacother 2008; 9 (18): 3243-9
44. Loeb LA, Essigmann JM, Kazazi F, et al. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A 1999; 96: 1492-7
45. Harris KS, Brabant W, Styrchak S, et al. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res 2005; 67: 1-9
46. Anderson JP, Daifuku R, Loeb LA. Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol 2004; 58: 183-205
47. De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 2004; 68: 2301-15
48. Mancini WR, De Clercq E, Prusoff WH. The relationship between incorporation of E-5-(2-Bromovinyl)-2′-deoxyuridine into herpes simplex virus type 1 DNA with virus infectivity and DNA integrity. J Biol Chem 1983; 258: 792-5
49. Chu CK, Ma T, Shanmuganathan K, et al. Use of 2′-fluoro-5-methyl- beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39: 979-81
50. Yao GQ, Liu SH, Chou E, et al. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil. Biochem Pharmacol 1996; 51: 941-7
51. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45: 1172-8
52. Chong Y, Chu CK. Understanding the molecular mechanism of drug resistance of anti-HIV nucleosides by molecular modeling. Front Biosci 2004; 9: 164-86
53. Bryant ML, Bridges EG, Placidi L, et al. L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45: 229-35
54. Shim J, Larson G, Lai V, et al. Canonical 3′-deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase. Antiviral Res 2003; 58: 243-51